NDAORALTABLETPriority Review
Approved
Oct 1958
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DIABINESE (chlorpropamide) is an oral small-molecule sulfonylurea antidiabetic agent approved in 1958 for managing type 2 diabetes mellitus. It works by stimulating insulin secretion from pancreatic beta cells and improving insulin sensitivity. This is a legacy product with significant historical importance in diabetes treatment.
LOE Approaching
Product is in late-stage lifecycle with minimal commercial expansion; brand teams are likely focused on managed decline and cost optimization rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on DIABINESE offers limited career advancement; the product is in managed decline with minimal job openings and shrinking market opportunity. Career professionals should view this assignment as a stepping stone to growth-stage products rather than a long-term strategic role.
Brand ManagerSales Representative
Worked on DIABINESE at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.